Max Hasmann
Impact in
- Geriatrics and Gerontology top 0.5%
- Sirtuins and Resveratrol in Medicine
- Oncology top 2%
- HER2/EGFR in Cancer Research
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
Papers in
- Oncology 32
- HER2/EGFR in Cancer Research 26
-
- Monoclonal and Polyclonal Antibodies Research 20
- Radiopharmaceutical Chemistry and Applications 4
- Co-authors
- Werner Scheuer (6 shared papers)Thomas Friess (6 shared papers)Birgit Bossenmaier (2 shared papers)Josef Endl (1 shared paper)Helmut Burtscher (1 shared paper)R. Löser (4 shared papers)Benno Rattel (2 shared papers)Simon P. Langdon (6 shared papers)
- Journals
- Molecular Cancer Therapeutics (4 papers)Clinical Cancer Research (3 papers)Biochemical Pharmacology (2 papers)Cancer Research (2 papers)Cancer Treatment Reviews (2 papers)
- Partner nations
- GermanyUnited KingdomSwitzerland
In The Last Decade
Max Hasmann
46 papers receiving 2.3k citations
Max Hasmann's Hit Papers
Peers
Comparison fields: 5 of 109
- Geriatrics and Gerontology 367
- Oncology 1.3k
- Physiology 222
- Radiology, Nuclear Medicine and Imaging 635
- Cancer Research 178
Countries citing papers authored by Max Hasmann
This map shows the geographic impact of Max Hasmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Hasmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Hasmann more than expected).
Fields of papers citing papers by Max Hasmann
This network shows the impact of papers produced by Max Hasmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Hasmann. The network helps show where Max Hasmann may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Hasmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Hit paper breakdown → | 2003 | 524 |
| 2 | Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models Hit paper breakdown → | 2009 | 490 |
| 3 | 2013 | 92 | |
| 4 | 2005 | 81 | |
| 5 | 2005 | 80 | |
| 6 | WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. | 2002 | 79 |
| 7 | 2012 | 63 | |
| 8 | 2018 | 60 | |
| 9 | 1994 | 59 | |
| 10 | 1989 | 57 | |
| 11 | 2013 | 56 | |
| 12 | Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. | 2006 | 53 |
| 13 | 2007 | 52 | |
| 14 | 1993 | 48 | |
| 15 | 2011 | 48 | |
| 16 | 2018 | 45 | |
| 17 | 1995 | 43 | |
| 18 | 2009 | 42 | |
| 19 | 2017 | 39 | |
| 20 | 2012 | 38 |
About Max Hasmann
Max Hasmann is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Immunology and Allergy and Genetics, having authored 50 papers that have together received 2.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (26 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), Cell Adhesion Molecules Research (7 papers), Estrogen and related hormone effects (5 papers), Glycosylation and Glycoproteins Research (4 papers), Cancer therapeutics and mechanisms (4 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cell death mechanisms and regulation (3 papers). The work is most often cited by research in Geriatrics and Gerontology (367 citations), Oncology (1.3k citations), Physiology (222 citations), Radiology, Nuclear Medicine and Imaging (635 citations) and Cancer Research (178 citations). Max Hasmann has collaborated with scholars based in Germany, United Kingdom and Switzerland. Frequent co-authors include Werner Scheuer, Thomas Friess, Birgit Bossenmaier, Josef Endl, Helmut Burtscher, R. Löser, Benno Rattel, Simon P. Langdon, Katja Wosikowski and Peter Mullen. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Biochemical Pharmacology, Cancer Research and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.